Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

Characteristics and Predictors of Early Deaths in Newly Diagnosed Classical Hodgkin Lymphoma

Cong Sun, Xianhuo Wang, Huilai Zhang

Blood (2024) 144 (Supplement 1): 1671.

https://doi.org/10.1182/blood-2024-208102

Published: 2024

Journal Articles

Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Blood (2024) 144 (Supplement 1): 3120.

https://doi.org/10.1182/blood-2024-206700

Published: 2024

Journal Articles

Analysis of the Nervous System Adverse Events Associated with Blinatumomab: A Real-World Study Using the FDA Adverse Event Reporting System Database

Wen Gao, Yaxiao Lu, Xianhuo Wang, Huilai Zhang

Blood (2024) 144 (Supplement 1): 2355.

https://doi.org/10.1182/blood-2024-201919

Published: 2024

Journal Articles

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study

Zhao Peiqi, Shu Zhao, Chen Huang, Jiesong Wang, Junqing Xu, Lanfang Li, Zhengzi Qian, Wei Li, Shiyong Zhou, Lihua Qiu, Xianming Liu, Ying Chen, Yanan Jiang, Yanbin Zheng, Daoguang Chen, Yuhuan Gao, Qingyuan Zhang, Huilai Zhang

Blood (2024) 144 (Supplement 1): 3730.

https://doi.org/10.1182/blood-2024-205438

Published: 2024

Journal Articles

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Zheng Song, Ying Cheng, Haiyan Yang, Liling Zhang, Liqun Zou, Ye Guo, Junning Cao, Huiqiang Huang, Zhao Wang, Sha Huang, Yiqian Fang, Jiaoyan Lyu, Keshu Zhou, Huilai Zhang

Blood (2024) 144 (Supplement 1): 986.

https://doi.org/10.1182/blood-2024-193167

Published: 2024

Journal Articles

Selinexor Induces DLBCL Cell Senescence Mediated By USP1/MDMX/p53 Axis

Yidan Zhang, Xiyue Xu, Xianhuo Wang, Huilai Zhang

Blood (2024) 144 (Supplement 1): 4174.

https://doi.org/10.1182/blood-2024-201248

Published: 2024

Journal Articles

Phosphorylation-Dependent ANXA2 Relocation on the Membrane and TLR4 Engagement: A Novel Signaling Axis Promoted By PIM1 Mutation in Diffuse Large B Cell Lymphoma

Yaxiao Lu, Ning Zhang, Yidan Zhang, Xiyue Xu, Xianhuo Wang, Huilai Zhang

Blood (2024) 144 (Supplement 1): 2962.

https://doi.org/10.1182/blood-2024-206311

Published: 2024

Journal Articles

Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with Brentuximab Vedotin (BV)-Based Treatment Options in China

Hengge Xu, Wei Li, Xianhuo Wang, Huilai Zhang

Blood (2024) 144 (Supplement 1): 6537.

https://doi.org/10.1182/blood-2024-207221

Published: 2024

Journal Articles

Clinical Efficacy and Safety Evaluation of Isazomib Based Combination Regimen for Multiple Myeloma First-Line Therapy

Yan Bai, Yuhuan Gao, Lihong Liu, Lanping Diao, Xiaolin Wu, Shaoning Yin, Huilai Zhang, Chen Huang

Blood (2024) 144 (Supplement 1): 7029.

https://doi.org/10.1182/blood-2024-205537

Published: 2024

Journal Articles

Multicellular Dynamics at Spatial Single-Cell Resolution Reveal Early Relapse of Hepatitis B Virus-Associated Follicular Lymphoma

Yuwei Deng, Qingyuan Zhang, Huilai Zhang, Jianli Ma

Blood (2024) 144 (Supplement 1): 6179.

https://doi.org/10.1182/blood-2024-193008

Published: 2024

Journal Articles

Clinical Characteristics and Initial Treatment Patterns of Mantle Cell Lymphoma in Btki Era: A Multi-Center Real-World Study in China

Mengya Cong, Junlei Jia, Zhanli Liang, Luming Cao, Huilai Zhang, Wenyu Li, Ou Bai, Haiwen Huang

Blood (2024) 144 (Supplement 1): 7813.

https://doi.org/10.1182/blood-2024-204982

Published: 2024

Journal Articles

Molecular Mechanistic Insights and Real-World Clinical Outcomes of Selinexor in Diffuse Large B-Cell Lymphoma

Wenqi Zhang, Yuhuan Gao, Lanping Diao, Lihong Liu, Guangyu Ma, Guimin Zhao, Haisheng Liu, Huilai Zhang, Chen Huang

Blood (2024) 144 (Supplement 1): 6184.

https://doi.org/10.1182/blood-2024-203366

Published: 2024

Journal Articles

Risk Stratification for Diffuse Large B-Cell Lymphoma Integrating Interim 18 f-FDG PET-CT Analysis and the National Comprehensive Cancer Network IPI: A Multicentre Retrospective Study

Jiesong Wang, Xianhuo Wang, Huilai Zhang

Blood (2024) 144 (Supplement 1): 6432.

https://doi.org/10.1182/blood-2024-202458

Published: 2024

Journal Articles

Latest Update Results of Cmoep Regimen in Treatment-Naive Patients with Peripheral T-Cell Lymphoma

Jingwei Yu, Xiuhua Sun, Guangxun Gao, Li Yu, Jiesong Wang, Lihua Qiu, Zhengzi Qian, Wei Li, Huilai Zhang

Blood (2024) 144 (Supplement 1): 6403.

https://doi.org/10.1182/blood-2024-204337

Published: 2024

Journal Articles

A China Survey on the Insights of Patients Living with Follicular Lymphoma: The Real-World Patient Journey Analysis

Yang He, Huilai Zhang, Bing Xu, Zengjun Li, Zheng Song, Qiuhui Jiang, Hui Wang, Weili Zhao

Blood (2024) 144 (Supplement 1): 7622.

https://doi.org/10.1182/blood-2024-206977

Published: 2024

Journal Articles

A Retrospective Analysis of Efficacy and Safety of Orelabrutinib Maintenance in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Zhiming Li, Jun Fang, Huilai Zhang, Wei Wang, Hui Li, Hui Zhou, Liqun Zou, Hong Cen, Wen Shujuan, Wuping Li, Peng Sun, Panpan LIU, Hang Yang, Yu Wang

Blood (2024) 144 (Supplement 1): 6542.

https://doi.org/10.1182/blood-2024-204292

Published: 2024

Journal Articles

Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Muhit Ozcan, Won Seog Kim, Huilai Zhang, Maria Bouzani, Zsolt Nagy, Hun Chuah, Gilles Salles, Edwin E. Jeng, Jiangeng Huang, Mariana Sacchi, Yajian Jiang, Adrian Minson

Blood (2024) 144 (Supplement 1): 4502.1.

https://doi.org/10.1182/blood-2024-198700

Published: 2024

Journal Articles

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Blood (2024) 144 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2024-204513

Published: 2024

Journal Articles

Magnesium Is Associated with Favorable Outcomes of Cancer Patients Treated with Immune Checkpoint Inhibitors

Yingfang Feng, Meng Gao, Hengqi Liu, Xianhuo Wang, Huilai Zhang

Blood (2024) 144 (Supplement 1): 6365.

https://doi.org/10.1182/blood-2024-202291

Published: 2024

Journal Articles

Sintilimab Plus Gemcitabine, Cisplatin, and Dexamethasone As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma：a Multicenter Retrospective Study

Blood (2024) 144 (Supplement 1): 6355.

https://doi.org/10.1182/blood-2024-194674

Published: 2024

NARROW

Characteristics and Predictors of Early Deaths in Newly Diagnosed Classical Hodgkin Lymphoma

Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Analysis of the Nervous System Adverse Events Associated with Blinatumomab: A Real-World Study Using the FDA Adverse Event Reporting System Database

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Selinexor Induces DLBCL Cell Senescence Mediated By USP1/MDMX/p53 Axis

Phosphorylation-Dependent ANXA2 Relocation on the Membrane and TLR4 Engagement: A Novel Signaling Axis Promoted By PIM1 Mutation in Diffuse Large B Cell Lymphoma

Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with Brentuximab Vedotin (BV)-Based Treatment Options in China

Clinical Efficacy and Safety Evaluation of Isazomib Based Combination Regimen for Multiple Myeloma First-Line Therapy

Multicellular Dynamics at Spatial Single-Cell Resolution Reveal Early Relapse of Hepatitis B Virus-Associated Follicular Lymphoma

Clinical Characteristics and Initial Treatment Patterns of Mantle Cell Lymphoma in Btki Era: A Multi-Center Real-World Study in China

Molecular Mechanistic Insights and Real-World Clinical Outcomes of Selinexor in Diffuse Large B-Cell Lymphoma

Risk Stratification for Diffuse Large B-Cell Lymphoma Integrating Interim 18 f-FDG PET-CT Analysis and the National Comprehensive Cancer Network IPI: A Multicentre Retrospective Study

Latest Update Results of Cmoep Regimen in Treatment-Naive Patients with Peripheral T-Cell Lymphoma

A China Survey on the Insights of Patients Living with Follicular Lymphoma: The Real-World Patient Journey Analysis

A Retrospective Analysis of Efficacy and Safety of Orelabrutinib Maintenance in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Magnesium Is Associated with Favorable Outcomes of Cancer Patients Treated with Immune Checkpoint Inhibitors

Sintilimab Plus Gemcitabine, Cisplatin, and Dexamethasone As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma：a Multicenter Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only